H

Harrow

Compounds ophthalmic formulations; markets branded drugs

Regional Sales Director

Full-Time
No salary listed
Expert
Bachelor's
Remote in USA
RemoteTravel in the field up to 50% of the time, including overnight stays.
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor's degree in marketing, business, or a related field is required.
  • 10+ years of sales and sales management experience in pharmaceuticals or medical devices is preferred.
  • Experience leading and mentoring first-line sales leaders.
  • Ability to travel in the field up to 50% of the time, including overnight stays.
  • Experience executing targeted business plans around priorities and goals.
  • Proficiency with Microsoft Office products and ability to learn additional software as required.
  • Possess a current and valid driver's license.
Responsibilities
  • Identify, recruit, coach, and retain top talent for the Ocular Surface Team.
  • Lead seven first-line leaders to grow sales through key account development, coaching, management, and mentoring.
  • Proactively manage the team's customer-facing activity levels as a leading indicator of sales performance, and take corrective action as needed to align individual activity with business goals and revenue requirements.
  • Balance a multi-product portfolio of products.
  • Provide detailed and accurate sales forecasting for each Area Sales Manager and their associated territories.
  • Routinely review Area Sales Manager and field sales team performance against goals and customer activity.
  • Work in person with each Area Sales Manager at least twice per year and with the field sales team as needed.
  • Assess and refine individual Area Sales Manager skill sets, and define and implement corrective actions to maximize sales impact and manager development.
  • Assist sales leadership efforts with the field sales team in reviewing sales performance, call activity, and sales development, including Field Coaching Reports with the sales manager.
  • Partner with Market Access and Trade to build pull-through plans for commercial, Medicare Part D, and Medicaid coverage wins across the geography.
  • Ensure the team uses patient support, pharmacy networks, and other access resources.
  • Assist the Vice President of Sales in leading training and development for Area Sales Managers across the team.
  • Partner with Sales Training on onboarding curriculum, workshops, and sustainment training for the field.
  • Manage the Ocular Surface Team's budget and resources.
  • Manage business expenses and travel responsibly.
  • Meet or exceed monthly, quarterly, and yearly revenue goals.
  • Execute national sales plans to achieve objectives.
  • Oversee and evaluate sales performance, adjusting as needed to meet competitive conditions.
  • Monitor customer, market, and competitor activity and update the organization accordingly.
  • Establish and maintain relationships with key opinion leaders and strategic partners.
  • Direct staffing, including recruitment, hiring, and training of additional team members, and deliver performance evaluations in accordance with company requirements.
  • Meet with key customers to assist Area Sales Managers and the sales team with negotiating and accelerating business.
  • Review and analyze Area Sales Manager and sales team performance and plans to determine effectiveness in achieving individual goals.
  • Lead sales activities and manage resources to deliver profitable organizational growth.
  • Assist the Vice President of Sales in planning and leading congresses and meetings associated with the portfolio.
  • Coach and mentor team members to achieve objectives through consultative and value-based communications.
  • Use resources to enhance productivity and provide optimal customer satisfaction.
  • Work closely with Commercial Leadership to support future success.
  • Understand the customer relationship management process, Life Science Cloud, reporting metrics, and forecasting.
  • Work with Human Resources to manage lower-performing and underperforming sales team members effectively.
  • Participate in national, regional, and local meetings.
  • Model Harrow values and ensure team members follow all compliance policies and procedures.
  • Carry out additional responsibilities based on team needs.
Desired Qualifications
  • Pharmaceutical or medical-device eye care experience, ideally in dry eye or ocular surface disease.
  • Commercial experience outside of sales, such as Marketing, Operations, Training, or Market Access.

About the company

Harrow focuses on eyecare pharmaceuticals, combining a compounding business (ImprimisRx) with a portfolio of FDA-approved branded drugs and biosimilars, plus biotech investments. Its products include customized compounded sterile and topical eye medications delivered directly to physicians and patients, alongside branded drugs acquired from other companies. The company differentiates itself by integrating a direct-to-physician compounding platform with an expanding branded drug portfolio, biosimilars, and owned production and distribution facilities across all 50 states. Its goal is to provide accessible, high-quality eye medications and grow its commercial and biotech assets to serve surgeons, hospitals, and patients nationwide.

Company Size

201-500

Company Stage

IPO

Headquarters

Nashville, Tennessee

Founded

1998

Get referred to Harrow

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue rose 11% to $70.7 million, with guidance reaffirmed at $350 million-$365 million.
  • A top-three PBM gave VEVYE access to millions of lives effective August 1, 2026.
  • BYOOVIZ launched July 2026, and TYRVAYA could add over $30 million revenue in 2027.

What critics are saying

  • VEVYE pricing and gross-to-net issues cut Q1 2026 revenue by $8 million.
  • OSRX appealed the October 2025 judgment, delaying Harrow's collection and distraction benefits.
  • TYRVAYA adds $20 million annual SG&A and $70 million contingent payments, pressuring margins.

What makes Harrow unique

  • Harrow bundles compounding, branded drugs, and biosimilars under one ophthalmology-only platform.
  • BYOOVIZ launched July 2026, entering the anti-VEGF market beside IHEEZO and TRIESENCE.
  • VEVYE, TYRVAYA, and VERKAZIA target dry-eye and allergic-eye niches with specialized distribution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

32%

1 year growth

31%

2 year growth

31%
Yahoo Finance
Aug 20th, 2026
Harrow reaffirms $350M-$365M guidance despite light H1, needs $235M-$250M in H2 to meet target

Harrow reported first-half 2026 revenue of around $115 million, below expectations due to VEVYE pricing changes. The company maintained full-year guidance of $350 million to $365 million, requiring $235 million to $250 million in second-half revenue. IHEEZO delivered record quarterly demand of 65,477 units despite losing pass-through reimbursement, whilst ordering accounts grew 32% year-over-year. VEVYE prescriptions increased 21% sequentially, outpacing the 14% broader market growth, with market share rising to 14.6%. TRIESENCE demand surged 162% year-over-year to 14,529 units. However, adjusted EBITDA remained negative at $1.2 million. The pending TYRVAYA acquisition adds $20 million in annual costs. Hedge fund ownership declined from 24 to 22 funds, whilst short interest stands at 20.14% of float.

Yahoo Finance
Aug 11th, 2026
Harrow reiterates $350M–$365M revenue guidance, plans $30M TYRVAYA acquisition

Harrow reported second-quarter revenue of $70.7 million, up 11% year-over-year, driven by stronger demand for VEVYE, IHEEZO and specialty products. The ophthalmic pharmaceutical company reiterated full-year revenue guidance of $350 million to $365 million and adjusted EBITDA guidance of $80 million to $100 million. VEVYE generated $29.4 million in quarterly revenue, up nearly 58% year-over-year, whilst IHEEZO contributed $15.6 million. Management expects second-half growth from improved VEVYE pricing, IHEEZO's 25% net price increase, and the BYOOVIZ and VERKAZIA launches. Harrow plans to acquire global rights to TYRVAYA for $30 million in cash, expecting more than $30 million of revenue in 2027 if the deal closes. The company also advanced pipeline programmes G-MELT and YOCHIL, targeting FDA submissions in 2027.

Associated Press
Jul 1st, 2026
Harrow launches BYOOVIZ biosimilar in $9B US anti-VEGF market under Samsung Bioepis deal

Harrow has announced the commercial launch of BYOOVIZ (ranibizumab-nuna) in the United States, an FDA-approved biosimilar referencing LUCENTIS. The launch follows Harrow's exclusive US commercialisation agreement with Samsung Bioepis, which also includes rights to OPUVIZ (aflibercept-yszy), another ophthalmology biosimilar. BYOOVIZ is approved for treating Neovascular Age-Related Macular Degeneration, Macular Edema following Retinal Vein Occlusion, and Myopic Choroidal Neovascularization. It was designated by the FDA as the first interchangeable ophthalmology biosimilar in the US. The product joins Harrow's expanding retina franchise, which includes IHEEZO and TRIESENCE. The company aims to strengthen its position in the estimated $9 billion US anti-VEGF market, providing retina specialists with buy-and-bill products for treating sight-threatening retinal diseases.

Yahoo Finance
Jun 10th, 2026
Harrow re-launches VERKAZIA to treat vernal keratoconjunctivitis in children

Harrow has re-launched VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, a prescription therapy for vernal keratoconjunctivitis (VKC), a serious allergic eye disease primarily affecting children. The re-launch includes a comprehensive commercial strategy focused on physician education, patient access and affordability initiatives. VERKAZIA is a calcineurin inhibitor immunomodulator that targets VKC's underlying inflammatory mechanisms and may reduce the need for steroid rescue, which carries risks including glaucoma or cataract formation. VKC can lead to sight-threatening conditions if left untreated. Chief Executive Officer Mark Baum said the re-launch aims to ensure dependable supply and remove access barriers for this evidence-based, steroid-sparing treatment. VERKAZIA represents the second of three priority products in Harrow's portfolio currently being executed.

Yahoo Finance
May 20th, 2026
B.Riley cuts Harrow price target to $60 amid pricing pressure but maintains buy rating

Harrow, Inc. (NASDAQ:HROW) had its price target reduced to $60 from $65 by B.Riley on 14 May, though the firm maintained its Buy rating. The adjustment followed first-quarter results impacted by weaker pricing for VEVYE and lowered near-term growth expectations. The Nashville-based ophthalmic pharmaceutical company reported first-quarter revenue of $44.2 million, including an $8 million non-recurring adjustment related to VEVYE commercial coverage. Despite pricing pressures, the company highlighted record VEVYE prescriptions and strong performance from IHEEZO and TRIESENCE, with unit demand rising 18% and doubling respectively year over year. Harrow reaffirmed full-year revenue guidance of $350–$365 million. B.Riley cited upcoming product launches, reimbursement coding catalysts and expanding commercial leverage as factors supporting stronger second-half performance.